187 related articles for article (PubMed ID: 2083513)
1. Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
McTavish D; Young RA; Clissold SP
Drugs; 1990 Oct; 40(4):543-60. PubMed ID: 2083513
[TBL] [Abstract][Full Text] [Related]
2. Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension.
Salvadeo A; Villa G; Segagni S; Piazza V; Picardi L; Romano M; Parini J
Arzneimittelforschung; 1985; 35(3):623-5. PubMed ID: 2859865
[TBL] [Abstract][Full Text] [Related]
3. Cadralazine versus prazosin as second-step treatment in hypertensive patients on beta-blockers: a randomized multicentre study. The Italian Multicentre Study Group.
Caponnetto S; Valvo E; Mocarelli P; Alberti D; Savonitto S
Eur J Clin Pharmacol; 1991; 40(5):461-5. PubMed ID: 1679390
[TBL] [Abstract][Full Text] [Related]
4. Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension.
Catalano M; Parini J; Romano M; Libretti A
Eur J Clin Pharmacol; 1985; 28(2):135-8. PubMed ID: 3886402
[TBL] [Abstract][Full Text] [Related]
5. Cadralazine and chlorthalidone as a second-step drug with atenolol in hypertensive patients: differences in blood pressure control during exercise.
Costa FV; Borghi C; Mussi A; Ambrosioni E
Eur J Clin Pharmacol; 1986; 30(2):145-50. PubMed ID: 3709638
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive activity of cadralazine in experimental hypertensive rats.
Takeyama K; Ikeno A; Minato H; Fukuya F; Nishimura S; Hosoki K; Kadokawa T
Arch Int Pharmacodyn Ther; 1988; 291():163-74. PubMed ID: 3365060
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker.
Buoninconti R; Motolese M
Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):613-6. PubMed ID: 2867048
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic effects of cadralazine or chlorthalidone in verapamil-treated elderly hypertensives.
Antonicelli R; Savonitto S; Tomassini PF; Gambini C; Sardina M; Paciaroni E
Int J Clin Pharmacol Ther; 1994 Apr; 32(4):198-203. PubMed ID: 8032580
[TBL] [Abstract][Full Text] [Related]
9. Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics.
Persson B; Granerus G; Wysocki M; Hedner T; Andersson OK
Eur J Clin Pharmacol; 1987; 31(5):513-8. PubMed ID: 2881788
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cadralazine in hypertensive patients.
Leonetti G; Parini J; Visconti M; Gradnik R
Eur J Drug Metab Pharmacokinet; 1988; 13(4):295-300. PubMed ID: 3243325
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of cadralazine in a large group of hypertensive patients chronically treated with cadralazine: advantage over a conventional study in a small group of patients.
Lecaillon JB; Dubois JP; Darragon T; Motolese M; Racine A; Ducret F; Grouberman D; Cordonnier D; Chanard J; Glorioso M
Ther Drug Monit; 1991 Mar; 13(2):103-8. PubMed ID: 2053115
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the antihypertensive activity of cadralazine (ISF 2469) and dihydralazine during chronic treatment.
Strocchi E; Costa FV; Caldari R; Malini PL; Marata AM; Parini J; Ambrosioni E
Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):519-23. PubMed ID: 6642790
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily.
Marichal JF; Brunel P; Lecaillon JB; Godbillon J; Faller B; Brignon P; Ménard J
Eur J Drug Metab Pharmacokinet; 1992; 17(3):213-20. PubMed ID: 1490491
[TBL] [Abstract][Full Text] [Related]
14. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
Friedel HA; Brogden RN
Drugs; 1990 Jun; 39(6):929-67. PubMed ID: 2196168
[TBL] [Abstract][Full Text] [Related]
15. Cadralazine challenge in patients with previous hydralazine-induced lupus: a 6-month study.
Pålsson L; Weiner L; Englund G; Henning M
Clin Pharmacol Ther; 1989 Aug; 46(2):177-81. PubMed ID: 2758727
[TBL] [Abstract][Full Text] [Related]
16. Cadralazine for the treatment of preeclampsia. An open, noncomparative, dose-finding pilot study.
Voto LS; Lapidus AM; Catuzzi P; Uranga Imaz F; Zin C; Margulies M
Hypertension; 1992 Feb; 19(2 Suppl):II132-6. PubMed ID: 1735567
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of oxdralazine and dihydralazine in essential hypertension.
Salvadeo A; Villa G; Segagni S; Piazza W; Criscuolo D
Int J Clin Pharmacol Ther Toxicol; 1981 Aug; 19(8):372-6. PubMed ID: 7030978
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug.
Semeraro C; Dorigotti L; Banfi S; Carpi C
J Cardiovasc Pharmacol; 1981; 3(3):455-67. PubMed ID: 6168827
[TBL] [Abstract][Full Text] [Related]
19. Manidipine: a review of its use in hypertension.
Cheer SM; McClellan K
Drugs; 2001; 61(12):1777-99. PubMed ID: 11693466
[TBL] [Abstract][Full Text] [Related]
20. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.
Goa KL; Wagstaff AJ
Drugs; 1996 May; 51(5):820-45. PubMed ID: 8861549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
